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Development of cytarabine prodrugs and delivery systems for 
leukemia treatment 
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Abstract 
Importance of the field: Cytarabine is a polar nucleoside drug used for the treatment of 
myeloid leukemia and non-Hodgkin’s lymphoma. The drug has a short plasma half-life, 
low stability, and limited bioavailability. Overdosing of patients with continuous infusions 
may lead to side effects. Thus, various prodrug strategies and delivery systems have 
been extensively explored to enhance the half-life, stability, and delivery of cytarabine. 
Among the recent cytarabine prodrugs, amino acid conjugate ValCytarabine and fatty 
acid derivative CP-4055 (in phase 3 trials) have been investigated for the treatment of 
leukemia and solid tumors, respectively. Alternatively, delivery systems of cytarabine 
have emerged for the treatment of different cancers. The liposomal-cytarabine 
formulation (DepoCyt®) has been approved for the treatment of lymphomatous 
meningitis.  
Areas covered in this review: Various prodrug strategies evaluated for cytarabine are 
discussed. Then, the review summarizes the drug delivery systems that have been 
used for more effective cancer therapy.  
What reader will gain: This review provides in-depth discussion of the prodrug strategy 
and delivery systems of cytarabine derivatives for the treatment of cancer. The design 
of cytarabine prodrugs and delivery systems provide insights for designing the next 
generation of more effective anticancer agents with enhanced delivery and stability. 
Take home message: Strategies on designing cytarabine prodrug and delivery 
formulations showed great promise in developing effective anticancer agents with better 
therapeutic profile. Similar studies with other anticancer nucleosides can be an 
alternative approach to gaining access to more effective anticancer agents.  
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1. Introduction 
Blood cancers such as leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and 
myeloma are characterized by the abnormal production of malformed lymphocytes 
and/or other blood cells. The cancer cells multiply without control and accumulate in 
bone marrow, blood and lymphatic tissues, and thus interfere with healthy cells and 
immune cell production and function. Ultimately these events result in blood/lymphatic 
disorders, such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes 
based on affected tissue [1]. 
The malformed cells are results of one or more acquired mutations in DNA of 
lymphatic or blood forming stem cells, which on multiplication (clone formation) 
generate high number of abnormal white blood cells. For example, in chronic 
myelogenous leukemia (CML) acquired mutation affects hematopoietic stem cells. CML 
is characterized by presence of Philadelphia (Ph) chromosome generated through 
translocation and fusion of the Abelson oncogene (ABL) at chromosome 9 and the 
break-point cluster region (BCR) at chromosome 22 leading to the generation of a BCR-
ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein [2].  
Leukemia, lymphoma, and myeloma are diagnosed in all ages and account for the 
deaths of approximately 54,000 people in United States in 2010, nearly 9.5 percent of 
deaths from cancer in 2010. Leukemia is a one of the most fatal hematopoietic 
neoplasms and represents a wide range of blood cancers mainly related to abnormal 
increase in the number of white blood cells (leukocytes). The death toll is expected to 
increase as new cases are diagnosed annually, suggesting a highly fatal nature of 
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leukemia if unattended or untreated at early stages of development [3]. Thus, causes, 
diagnosis, treatment, and prognosis of leukemia are subjects of major interest. [4].  
Depending upon the type of abnormal early blast or mature cells present, leukemia 
can be categorized into acute or chronic forms, respectively. The acute leukemia is 
identified by the rapid increase of immature white blood cells that crowd and accumulate 
around bone marrow, and thus induce the haemopoietic organ inability to produce 
normal blood cells. Therefore, immediate and aggressive treatment is required in acute 
leukemia due to rapid progression and accumulation of the malformed cells, which with 
time, enter the bloodstream and invade other organs. Chronic leukemia is caused by 
the excessive build up of abnormal mature white blood cells, which takes time to 
progress [5]. Further, leukemia can be lymphoblastic or lymphocytic leukemias (LL) and 
myeloid or myelogenous leukemias (ML) depending upon type of blood cell affected. 
The lymphoblastic or lymphocytic leukemias occur due to the cancerous modifications 
of bone marrow cells that are converted to lymphocytes. Lymphocytes have roles as the 
infection-fighting immune system cells. The myeloid or myelogenous leukemias result 
from the cancerous change of marrow cell that form red blood cells, platelets, and white 
blood cells [6,7]. 
Owing to the heterogeneity of leukemia, treatment options for different classes of 
leukemias vary. The leukemia chemotherapy involves drugs from different classes 
ranging from kinase inhibitors to DNA synthesis inhibitors [8]. In many cases, a 
combination of two or more drugs is administered to patients to manage leukemia 
[9,10]. Radiotherapy is sometimes used along with chemotherapy in some types and 
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stages of blood cancer, such as acute lymphocytic leukemia (ALL) and B-Cell 
lymphomas [11,12]. 
Cytarabine (4-amino-1-β-D-arabinofuranosyl-2-(1H)-pyrimidinone, 1-β-D-
arabinofuranosylcytosine, araC, Cytosar-U) is a pyrimidine nucleoside-based anticancer 
drug (Figure 1) with arabinose sugar widely used for the treatment of leukemia. 
Cytarabine is predominantly used against acute myelogenous leukemia (AML) and non-
Hodgkin’s lymphoma (NHL), chronic myelocytic leukemia (blast phase), ALL and 
erythroleukemia [13,14]. It may be used alone or in combination with other anticancer 
agents, such as daunorubicin, doxorubicin, thioguanine, or vincristine. 
When cytarabine is used in combination with other anticancer drugs for the 
treatment of different leukemias and solid tumors [15,16], the drug combinations 
generally improve the cancer therapy by synergistic effect [17]. Cytarabine is used in 
induction therapy in combination with anthracyclines and in consolidation therapy at 
higher dose for AML patients. The combination of cytarabine with purine nucleoside 
analogs, such as fludarabine and cladribine, has been extensively explored in the 
treatment of patients with relapsed or refractory AML [18]. In Hodgkin’s disease (HD) 
and NHL, cytarabine is used in conjunction with other drugs using different regimens, 
such as DHAP (cytarabine-cisplatin-dexamethasone) [19] and ESHAP (etoposide-
methylprednisolone-cytarabine-cisplatin) [20] in patients with relapsed or refractory 
lymphoma. Cytarabine is used as front line drug for mantle cell lymphoma (MCL) [21]. 
Hyyper CVAD-MTX/Ara-c regimen (rituximab with hyperfractioned cyclophosphamide, 
doxorubicin, vincristine and dexamethasone plus methotrexate and cytarabine) is used 
for Burkitt’s leukemia/lymphoma [22] and ALL [23]. 
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Figure 1. Chemical structure of cytarabine.  
 
Cytarabine acts on rapidly dividing cells and inhibits DNA synthesis at S-phase of 
cell cycle and also hinders progression of cells from G1 phase to the S-phase. When 
inside the cell, cytarabine is converted into the triphosphate derivatives by kinase 
enzymes to show its cytotoxic effect. The exact mechanism of action of cytarabine 
triphosphate has not been elucidated but it appears to inhibit DNA polymerase by 
competing with deoxycytidine triphosphate [24] and thus reduces the cell replication.  
Cytarabine is a polar nucleoside and has a short plasma half-life. After three 
phosphorylation step, cytarabine is converted to cytarabine triphosphate. It has been 
suggested that cytarabine triphosphate inhibits DNA polymerase by competing with the 
natural substrate, deoxycytidine triphosphate, resulting in DNA synthesis inhibition. The 
low bioavailability of cytarabine is created by its low permeability across cell membrane 
and rapid conversion into inactive 1-β-D-arabinofuranosyluracil (AraU). The drug is 
rapidly converted into its uridine derivative by deamination of cytosine ring in the 
presence of cytidine deaminase [25]. Thus, continuous intravenous infusion of higher 
doses is required to maintain constant plasma level of the drug in 8 to 24 h. The higher 
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doses of cytarabine lead to toxicity on normal organs and side effects [26]. Alternatively, 
cytarabine is administered by subcutaneous infusion in which peak plasma levels are 
attained after 20 to 60 min and decrease below steady-state level after 100 min [27]. 
Understanding the mechanism of the action and metabolism of cytarabine has 
allowed many investigations to improve the low bioavailability and stability. These 
efforts, depending upon formulation and modification, can be divided into two major 
categories: prodrugs and drug delivery systems. The prodrug strategy for cytarabine 
involves the chemical modification or introduction of a potentiating group on parent drug 
while the delivery system involved in physical encapsulation of drug without introduction 
of any chemical modification on parent drug. The molecules synthesized for prodrug 
evaluation may have higher therapeutic effect while the delivery system may improve 
the effect in a particular tissue or organ. Various explored prodrug strategies and 
potential of delivery systems for cytarabine are discussed. 
 
2. Cytarabine Prodrugs 
Most of the therapeutic drugs have to pass physiological barriers before reaching 
to the target organ/tissue of action. Many drugs get modified into inactive derivatives 
during the transportation process. Among the various strategies used to minimize the 
undesirable metabolism of drug, prodrug approach offers a great promise in retention of 
pharmacological properties of drugs, improving the drug efficacy, decreasing the 
toxicity, or reduction in dose of administration.  
Prodrugs are defined as pharmacologically inert chemical derivatives that can be 
converted into the active drug molecules under in vivo physiological conditions through 
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an enzymatically or nonenzymatic process, to exert a therapeutic effect at desired target 
site. An Ideal prodrug is converted to the original therapeutically active form of drug at 
target organ and the substituted group is eliminated from the body [28]. Thus, prodrug 
approach may minimize undesirable toxicity related to the parent drug in non-targeted 
organs [29, 30].  
Many prodrugs have been developed to improve drug efficacy, absorption, 
bioavailability, instability, drug delivery, drug specificity, toxicity, membrane 
transportation, or patient adherence (like poor taste or odor of drug) [31,32]. Designing 
of prodrugs generally depends upon many factors including the mechanism of action, 
enzymatic interaction, lipophilicity, functional groups present on the drug and their 
lability, and metabolic pathway of drug.  
There have been major efforts on the development of cytarabine derivatives to 
generate compounds with higher therapeutic index for the treatment of leukemia and 
lymphoma (sections 2.1-2.3). Among the explored strategies, the prodrug strategy of 
introducing modifications on the parent drug to enhance plasma half-life or delivery to 
cancer cells is a subject of major interest.  
The prodrug design for cytarabine has been explored on the basis of mechanism 
of action and metabolism of the drug. The deamination of the cytosine base of 
cytarabine by cytidine deaminase leads to formation of uridine derivative (AraU) and 
deactivation of the drug. In general, cytarabine prodrugs have been designed either to 
circumvent its catabolism into AraU or to enhance cellular delivery. Some of the prodrug 
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approaches included designing amino acid-cytarabine, fatty acid-cytarabine, and amino 
acid-fatty acid-cytarabine derivatives (sections 2.1 and 2.2). 
Mechanistically, cytarabine acts as a prodrug itself and is converted 
intracellularly to cytarabine triphosphate through monophosphate and diphosphate 
derivatives before generating biological activities. In the process, monophosphorylation 
is the rate-limiting step in the metabolic conversion to triphosphate form. Alternatively, 
many phosphate derivatives of cytarabine have been evaluated as prodrugs to improve 
the cellular uptake of active metabolites (section 2.3). 
 
2.1 Amino acid derivatives 
Many amino acid and peptide derivatives are known to increase the cellular 
uptake of the drug molecules. Peptides with both nucleophilic group (-NH2) and 
electrophilic (-COOH) groups can be used for the conjugation of a large number of drug 
molecules. Amino acid or peptide attached to a drug can reduce the undesired 
metabolism by modification of the hydrolytic activity or the steric effect surrounding 
susceptible functional groups. Cytarabine derivatives substituted with amino acids at 4-
amino or 5′-hydroxyl positions have been synthesized and evaluated by different groups 
as described below. 
The amino acid-substituted derivatives of cytarabine at 4-amino position were 
designed to reduce the metabolism of cytarabine into uridine derivative by blocking the 
proximity of cytidine deaminase. Derivatization of cytarabine with a single amino acid at 
amino group reported by Jin et al. [33] involved the protection of hydroxyl groups by tert-
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butyldimethyl silyl (TBDMS) followed by the conjugation with protected amino acids. 
Amino acid derivatives synthesized with arginine, leucine and isoleucine (Figure 2) were 
evaluated for cellular uptake in Caco-2 cells and were compared with that of cytarabine. 
The arginine derivative was shown to have comparable uptake while the leucine and 
isoleucine derivatives reduced the uptake of drug. They have also compared the 
concentration dependency cellular uptake of the synthesized derivatives and found a 
similar uptake for cytarabine and arginine-cytarabine at increased concentrations while 
leucine-cytarabine and isoleucine-cytarabine derivatives showed less cellular uptake 
than that of the parent drug at higher concentrations.  
  
Figure 2. N4-substituted amino acid derivatives of cytarabine. 
 
Sun et al. reported the 5′-amino acid derivatives of cytarabine and compared 
their cellular uptake in Caco-2 and HELA cells [34] (Figure 3). Among the various amino 
acid derivatives, the 5′-valyl prodrug exhibited highest permeability across the Caco-2 
cells monolayer followed by the 5′-isoleucine derivative. Compared to L-Isomer of 
valine, D-isomer had significantly less cellular uptake, suggesting that the 
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stereochemical oligopeptide transporters may be involved in transporting amino acid 
prodrugs. Antiproliferative studies on the HL-60 cells showed the comparable activity of 
amino acid derivatives versus that of parent cytarabine. The antiproliferative effects of 
cytarabine and the amino acid ester prodrugs (IC50) in HL-60 Cells were reported as 
cytarabine (20 µM), 5′-L-valyl-cytarabine (16 µM), 5′-D-valyl-cytarabine (20 µM), 5′-L-
isoleucyl-cytarabine (21 µM), 5′-L-phenylalanyl-cytarabine (17 µM), 5′-D-phenylalanyl-
cytarabine (16 µM), and 5′-L-tryptophyl-cytarabine (19 µM). The study recommended 
the valyl prodrug as the potential candidate for the oral delivery of cytarabine in a similar 
fashion the other valyl prodrugs that have been reported to be promising with other 
nucleoside drugs for other conditions [35]. 
 
Figure 3. Structure of 5′-amino acid ester prodrugs. 
 
2.2 Fatty acid derivatives 
 The pharmacological properties of drugs depend upon overall surface 
interactions with medium and can be modulated by variation in the 
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lipophilicity/hydrophilicity ratio. The presence of long fatty acyl chains makes the drug 
molecules lipophilic [36]. Furthermore, the lipophilic drugs pass across the membrane 
rapidly and make the drug available for biological action at higher intracellular 
concentration in target cells. The fatty acid conjugation of the drugs through 
esterification or amidation leads to formation of ester or amide bond, respectively, with 
the drug molecule. The approach has two advantages: First, the conjugation protects 
the functional group. Second, the substitution allows sustained and continuous release 
of the drug through hydrolysis thus minimizing the side effects at higher doses of drugs. 
The prodrug approach using fatty acid derivatization at 5′-OH and 4-NH2 groups 
of cytarabine has been evaluated by many research groups. In addition to making the 
drug more lipophilic, the strategy may also allow the protection of cytarabine from 
cytidine deaminase enzyme action and thus preventing its metabolism into inactive form 
AraU.  
Fatty acid presence along with amino acid further utilizes the assumed properties 
of amino acid as well as fatty chains. Liu. et al. has used the advantage of simultaneous 
amino acid and fatty acid derivatization [37]. They reported N4-amino acid (Val, Met, 
Tyr, Glu and Arg) and fatty acid derivatives with chain length of 10, 14 and 18 carbons 
(Figure 4). The synthesis was accomplished through the direct coupling of amino acid-
fatty acyls derivatives and cytarabine at 4-NH2 (i.e., N4) position through a peptide 
bond. The synthesized derivatives showed variation in anti-proliferative activities with 
different amino acids and/or fatty acid. The studies performed using HL-60 and HELA 
cells showed potential reduction in IC50 with the substitution at N4. Among the different 
amino acids derivatives, the methionine derivative demonstrated better antiproliferative 
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activity when compared to the other synthesized conjugates. The antiproliferative 
activity was dependant on the chain length and decreased with increase in chain length 
at N4, suggesting that introduction of bulky groups at N4 through amide bond would not 
be beneficial in improving biological activity. 
 
Figure 4. Structure of fatty acid-amino acid-cytarabine derivatives. 
 
Fatty acids-substituted conjugates of cytarabine at 5′-OH showed significantly 
different behavior than N4 derivatives. Derivatization with different saturated and 
unsaturated higher fatty acids showed comparable activity to that of cytarabine in 
different cell lines [38]. Among the derivatives, CP-4055, a fatty acid derivative of 
cytarabine (ara-C-5′-elaidic acid ester) (Figure 5), facilitated and enhanced cellular 
accumulation and retention of ara-C in tumor cells. Unlike cytarabine, the cellular uptake 
of CP-4055 is independent of nucleoside transporters, and is believed to be via passive 
diffusion through the cellular membrane or an alternative internalization mechanism 
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[39]. CP-4055 is then hydrolyzed intracellularly by esterases to release free cytarabine, 
which is subsequently phosphorylated to the active triphosphate analog. When 
compared with cytarabine as a potent inhibitor of DNA synthesis [40], CP-4055 also 
transiently inhibits RNA synthesis. Furthermore, the fatty acyl conjugation potentially 
delayed inactivation to ara-U. CP-4055 is not a substrate for cytidine deaminase. CP-
4055 demonstrated cytotoxicity in solid tumor and leukemia cells in vitro and in vivo 
[41]. CP-4055 was evaluated against a lymphoma cell line with deficient nucleoside 
transport (5CEM-araC/C8) and was resistant to cytarabine. CP-4055 was able to kill a 
high proportion of drug-resistant cells by apoptosis [42]. Further studies of CP-4055 in 
human leukemia and lymphoma HL-60 and U937 cells demonstrated additive or 
synergistic cytotoxic activity in combination with other anticancer drugs, such as 
cloretazine, idarubicin, gemcitabine, irinotecan, and topotecan, [43]. 
Continued treatment with CP-4055 exhibited enhanced antitumor effect in human 
leukemia and in solid tumor models in vivo. The elaidic acid derivative of cytarabine was 
studied in phase 1 studies in patients with solid tumors, such as malignant melanoma, 
ovarian cancer, and non-small cell lung cancer. The pharmacokinetic study in 34 
patients demonstrated that at dose levels of >150 mg/m2 after 0.5-2 h intravenous 
infusion, CP-4055 was well tolerated and remained in plasma for up to 5-10 hr [44]. CP-
4055 under the brand name ElacytTM has now moved to phase 3 trials (NCT01147939) 
by Clavis Pharma in patients with late stage AML.  
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Figure 5. Structure of elaidic acid-cytarabine conjugate (CP-4055). 
 
The 2′-hydroxyl position of arabinose sugar in cytarabine was further explored for 
functionalizing with fatty acids. We synthesized and evaluated the 2′-O and 5′-O-
myristoyl and 2′,5′-dimyristoyl derivatives (Figure 6). As the cytotoxic mechanism of 
cytarabine involves phosphorylation of 5′-hydroxyl into triphosphate, the effectiveness of 
fatty acyl ester derivatives depends on the concentration of the parent drug delivered 
intracellularly after hydrolysis and availability of 5′-hydroxyl group for phosphorylation 
[45].  
5'-Substitution R2 = HR2 = myristoyl
R1 = C2H5SCH2, CH3CH2CH2
R1 = C2H5SCH2, CH3CH2CH2
2'-Substitution
2',5'-Disubstitution
O
OH
OH
N
N
NH2
O
OR1
O
O
OH
O
N
N
NH2
O
R2O
R1
O
 
Figure 6. Chemical structure of 5′-O-, 2′-O-monosubstituted and disubstituted 
cytarabine derivatives. 
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The 5′-substituted fatty acyl derivative of cytarabine was not able to inhibit 
significantly the proliferation of leukemia cells (CCRF-CEM) even after 96 h at a 
concentration of 1 µM. On the other hand, 2′,5′-dimyristoyl derivative of cytarabine and 
2′-fatty acyl derivatives of cytarabine inhibited the growth of cancer cells by 
approximately by ~36-76% at a concentration of 1 µM after 96 h incubation. 2′,5′-
Disubstituted derivative showed comparable activity to that of parent drug cytarabine 
and physical mixtures after 96 h. Enhanced cytotoxic activity of 2′,5′-disubstituted 
derivative after 96 h compared to that in 24 h indicate that the conjugate releases 
cytarabine slowly and may behave as a prodrug for sustained delivery of the parent 
nucleoside. Although the anticancer activity of the compound was only comparable to 
that of cytarabine after 96 h, the sustained-release property may be beneficial.  
 
2.3 Phosphate derivatives 
The phosphate prodrug approach has been widely used with nucleoside drugs 
[46]. Nucleosides are converted intracellularly into the monophosphate, diphosphate, 
and triphosphate derivatives, respectively, before generating biological activities. The 
monophosphorylation is generally the rate-determining step and thus delivery of 
monophosphorylated nucleosides that bypass this step is highly desired. Cytarabine is 
also converted into the triphosphate form before incorporation into nucleic acids. Thus, 
various phosphate derivatives of cytarabine have been synthesized and evaluated as 
discussed below.  
Lipophilic phosphate prodrugs of cytarabine were designed to contain both the 
phosphate and lipid (fatty chain) properties. The concept of using lipophilic nucleoside 
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monophosphate ester derivatives of cytarabine was proposed to bypass the first 
phosphorylation step and circumvent tumor resistance associated with decreased 
deoxycytidine kinase activity via kinase bypass. Furthermore, it was expected that 
metabolic degradation by cytidine deaminase to be reduced. Finally, partial masking of 
the phosphate charge and increased lipophilicity may allow higher intracellular levels of 
the parent analog [47,48,49].  
Initially, it was expected that cleavage of the prodrug moiety was due to the 
action of phosphodiesterase; however, it was subsequently demonstrated that the 
release of the parent drug occurs via successive two-carbon degradation via oxidation 
in peroxisomes [50]. The investigations led to discovery of the stearyl phosphate diester 
of cytarabine (cytarabine ocfosfate, YNK01) (Figure 7) [51]. Further clinical evaluation of 
cytarabine ocfosfate showed enhanced stability and higher half-life when compared with 
cytarabine and showed great promise for oral administration [52,53,54]. A phase 1/2 
study demonstrated that 15.8% of the total dose was absorbed and metabolized to 
cytarabine and AraU [55]. Cytarabine ocfosfate was approved in 1992 [56] in Japan by 
Nippon Kayaky under license from Yamasa Shoyu for use in patients with adult acute 
nonlymphocytic leukemia and myelodysplastic syndrome [57]. 
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Figure 7: Chemical structure of cytarabine ocfosfate. 
 
Among other phosphate derivatives, the 5′-protected phosphate triester 
derivatives of cytarabine have been also evaluated as prodrugs. Gouy et al. synthesized 
mixed phosphate triester derivatives of cytarabine [58] (Figure 8), which were expected 
to release intracellularly cytarabine monophosphate after esterase- and 
phosphodiesterase-mediated hydrolysis, respectively (Figure 9).  
 
Figure 8. Chemical structures of mixed phosphate araC prodrugs. 
 
Whereas other phosphotriester derivatives with other nucleoside drugs, such as 
AZT containing S-acyl-2-thioethyl (SATE) phenyl pronucleotides, have shown 
improvement in activity versus their parent nucleosides, these protected phosphate 
triester derivatives showed reduced activity against the leukemia cell lines when 
compared with that of cytarabine. The reduced antitumor activity observed with 
phosphotriester derivatives of cytarabine was assumed to be a result of the limited 
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cellular uptake, a reduced hydrolysis to the nucleoside monophosphate, extracellular 
hydrolysis to nucleoside monophosphate, or an unexpected decomposition mechanism 
that hampered the intracellular formation of the 5′-mononucleotide (araCMP). 
 
 
Figure 9. Possible mechanism of hydrolysis of a phosphotriester prodrug of cytarabine 
into a monophosphate derivative. 
 
To compare the hydrolysis of phosphotriester derivatives of nucleosides [58], 
three derivatives, cytarabine phosphotriester derivative, AZT phosphate prodrug, and 
snake venom phosphodiesterase (SVP)-substrate (p-nitrophenyl thymidinyl phosphate), 
were tested in presence of SVP (snake venom phosphodiesterase), a representative for 
the type I phosphodiesterase enzyme family at 37 °C. The hydrolysis led to the 
formation of the corresponding nucleoside 5′-monophosphate (Figure 9) with half-lives 
of 4.6 h for cytarabine derivative, 53 min for AZT derivative, and 43 min for p-nitrophenyl 
thymidinyl phosphate. Thus, 2′-deoxynucleotides were hydrolyzed faster than the 
corresponding ribonucleotides, and the araC metabolite appeared to be a poor 
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substrate for SVP when compared to AZT or thymidine. These data suggest that a slow 
hydrolysis to cytarabine monophosphate contributes to reduced antitumor activity. 
Phosphoramidate derivatives of cytarabine were also shown to have reduced 
anticancer activity when compared with cytarabine. For example, a nitrofuran 
phosphoramidate derivative (Figure 10) reported by Tobias et al. showed reduction in 
anti-proliferative activity when compared to that of cytarabine [59].  
  
Figure 10. Chemical structure of a cytarabine nitrofuran phosphoramidate. 
 
Phosphoramidate derivatives of cytarabine metabolite 2-β-D-arabinouridine 
(AraU) (Figure 11) were evaluated by Mehellou et al. [60]. The rationale for this study 
was to determine whether phosphorylation of AraU can activate the inactivate 
metabolite. Thus masked phosphate prodrug was synthesized for intracellular delivery. 
The compounds found to have reduced activity when compared with AraU. Hydrolysis 
studies in cell extract by NMR showed the reduced activity of phosphoramidate 
derivatives to hydrolysis because of the stability of P-N bond to hydrolysis. 
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Figure 11. Chemical structure of AraUphosphoramidates. 
 
In general, the biological activities of synthesized fatty acid, amino acid, and 
phosphate conjugates depended upon the mechanism and ease of intracellularly 
released cytarabine or monophosphate derivative. The phosphorylation process occurs 
on the 5′-OH group of the arabinose sugar. Prodrug strategies that used either the 
substitution at 4-amine group of cytosine base or the protected 5′-monophosphate 
derivatives have resulted in compromised activities against various cancers. 
 
3. Delivery Systems 
The drugs, which have poor solubility, low cell permeability, fast metabolism and 
elimination, or require continuous dosages for a longer period of time, could be 
encapsulated in a protected sheath or fast delivery vehicle without any covalent or 
chemical modification in drug structure. Various vehicles, sheaths, particles or systems 
have been introduced as drug delivery systems for improving the delivery of drug 
molecules to target organ in required dosages. Some of drug delivery systems or 
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vehicles include nanoparticles, polymers, hydrogels, organogels, niosomes, and 
liposomes. 
The nucleoside drugs are polar compounds and have generally low membrane 
permeability. A number of delivery systems evaluated with anticancer nucleoside drugs 
have been reviewed recently [61,62]. 
Cytarabine is a highly polar water soluble nucleoside. Various systems have 
been investigated for encapsulation and targeted delivery of cytarabine. The selection of 
cytarabine delivery systems [63] depends upon their encapsulating capacity. Some 
include nanoparticles, hydrogels, chitosan, niosome vesicles of tween 20, and 
liposomes. Liposomal cytarabine was approved by the FDA for the treatment of 
lymphomatous meningitis [64].  
 
3.1 Hydrogels 
Hydrogels are biomaterials consisting of a polymer matrix with a high water 
retention capacity. The hydrogels are capable of encapsulating the hydrophilic drugs. 
Sustained release of the drug depends on the polymer matrix constitution. The 
hydrogels have application as biomaterials since they have similarity in physical 
properties, such as water contents, soft consistency and low interfacial tension, to those 
of natural tissues in biological systems [65]. The encapsulation of hydrophilic drugs 
such as nucleoside analogs with hydrogels would be easy and loading could be 
expected higher compared to other polymers. On the other hand, the strong interaction 
among the polymer and drug would hinder the release.  
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Cytarabine has been studied with HEMA (2-hydroxyethyl methacrylate) [66] and 
HEMA copolymerized with acrylamide [67]. The study showed that the rate and total 
time of cytarabine release from the copolymer (hydrogels) can be partially modulated by 
varying the amount of monomer composition and degree of cross linking of the gels. 
Even though, hydrogels have not been completely successful for delivery of cytarabine, 
more studies with different polymer compositions can be used in finding the balanced 
system for drug encapsulation as well as sustained release.  
 
3.2 Liposomes 
Liposomes or lipid capsids have been important vehicles for the delivery of a 
number of drugs [68]. The liposomes are lipophilic systems and can pass the cell 
membranes easily [69]. They possess unique pharmacokinetic characteristics because 
of their nanometer size (ranges in mean diameter from 50 to 250 nm) as systemically 
administered vesicles [70]. These unique characteristic properties allow clearance via 
the reticuloendothelial system, which leads to a relatively long systemic circulation time, 
and hepatic and splenic distribution. Furthermore, the liposomes exhibit preferential 
extravasation and accumulation at the site of solid tumors due to increased endothelial 
permeability and reduced lymphatic drainage in these tissues [71]. The increased 
endothelial permeability has been defined as enhanced permeability and retention effect 
[72].  
Thus, liposomal delivery is a means to modify the pharmacokinetic and 
pharmacodynamic properties of anticancer agents [73], improving pharmacological 
properties, and reducing or modulating their toxicity profile [74]. Polar drugs once 
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encapsulated inside the liposomes are transported across the membranes by facilitated 
mechanism of liposome capsid. Liposomal cytarabine formulation has been studied with 
different liposomal compositions and hybrid systems with polymers [75].  
The cytarabine encapsulated liposome has been studied with thermosensitive 
hydrogels [76]. The hydrogel was based on the biodegradable chitosan and β-
glycerophosphate (C-GP) that are thermosensitive and act as a thermal trigger to 
regulate the drug release from encapsulation. Combining of liposomes with C-GP 
hydrogel system gave the advantages of more sustained release of cytarabine along 
with a higher stability of the hydrogel-liposome system compared to liposome alone. 
The investigators suggest hydrogel system is appropriate for controlled and sustained 
release of cytarabine.  
Cytarabine crosses the blood-brain barrier only to a limited extent after rapid i.v. 
administration. Liposomes with encapsulated cytarabine showed enhanced half-life and 
were found to be suitable for the treatment of lymphomatous meningitis. The formulation 
has been approved for the treatment of lymphomatous meningitis under the brand name 
(DepoCyt®) [77]. DepoCyt® formulation is prepared by encapsulation of a sterile 
suspension of cytarabine into multivesicular lipid based polymeric liposomal particles 
composed of cholesterol, triolein, dioleoylphosphatidylcholine (DOPC) and 
dipalmitoylphosphatidylglycerol (DPPG). DepoCyt® is administered as intrathecal 
injection in cerebrospinal fluid for the treatment of neoplastic meningitis as a sustained-
release formulation that maintains cytotoxic concentrations of cytarabine in 
cerebrospinal fluid for more than 14 days following a single injection [78,79].  
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Cytarabine has been used in the combination with anticancer drugs for 
synergistic antitumor activity. The combination of anticancer drugs as a cocktail is now 
commonly used clinically in cancer chemotherapy. Alternatively, two or more drugs can 
be encapsulated in the liposomes to enhance the delivery. The combination of 
cytarabine with daunorubicin HCl (a DNA intercalator) in 5:1 ratio in a liposomal 
formulation (cytarabine/daunorubicin HCl liposome injection) has been used by 
intravenous infusion for synergistic therapy in the leukemia treatment as CPX-351 [80]. 
The liposome membrane is composed of distearoylphosphatidylcholine (DSPC), 
distearoylphosphatidylglycerol (DSPG), and cholesterol in a 7:2:1 molar ratio. The 
liposomal formulation (CPX-351) demonstrated enhanced therapeutic activity in 
preclinical tumor models [81] and promising anticancer activity in a phase I clinical trial 
in patients with hematological malignancies [82,83]. 
The substituted derivatives of cytarabine have also been encapsulated in 
liposomes to improve the delivery and anticancer activity. Schwendener et al. studied 
the encapsulation of N4-fatty acyl derivatives in liposomes and evaluated their potency 
compared to cytarabine liposomes [84]. The lipophilic N4-hexadecyl cytarabine (a 
potent derivative among N4-fatty acyl derivatives) was encapsulated in liposomes and 
evaluated in a cologenic assay with HL-60 cells showing comparable activity with 
cytarabine. On the other hand, the liposomal formulation showed higher cytotoxicity in 
cytarabine resistant cell line compared to that of parent cytarabine [85]. The cellular 
uptake of liposomal cytarabine derivative was found to be five times more than 
cytarabine [86]. Similarly among other derivatives of cytarabine N4-octadecyl cytarabine 
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also showed a similar behavior. After intravenous injection, the liposomal formulation 
showed longer plasma half-life compared to cytarabine [87,88].  
 
3.3 Nanoparticles 
Nanometer size particles have higher delivery through enhanced permeability to 
the tumor sites [89]. Drugs attached or encapsulated are delivered at higher 
concentrations to the site of action and are protected from fast excretion [90]. The 
polymeric nanoparticles have been extensively investigated for the delivery of various 
drugs [91,92].  
Rukmani et al. investigated the methacrylic acid polymeric nanoparticles 
encapsulation of cytarabine [93]. Detailed morphological analysis of nanoparticles and 
further in vivo study of hematological parameters after administering CTH nanoparticles 
continuously for 9 days to tumor bearing mice showed improvement in lifespan of 
leukemia mice by the formulation when compared to cytarabine alone. The 
nanoparticular cytarabine formulation was able to restore the altered physiological 
parameters of leukemic mice to the normal levels and found to have improved 
pharmacokinetics profile and prolonged the lifespan of mice with increased white blood 
cells count that make the nanoparticle a potential carrier for the cytarabine.  
 
3.4 Other Delivery systems 
Among other systems that can serve as delivery vehicles, the natural or artificial 
polymers/molecules that are biocompatible have been evaluated to improve the delivery 
of the drug. Some systems include chitosan [94] and niosome vesicles [95] of tween-20 
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and tween-80 [96,97]. With these systems little success has been made in getting the 
final applicable system because of insufficient release of the drug from the conjugates.  
In conclusion, among the delivery systems evaluated for application of 
cytarabine, liposomal formulation has been successful in increasing the half-life and 
found application in treatment of lymphomatous meningitis. The other systems have 
shown promising improvement in delivery and require more systemic study for final 
application. 
 
4. Conclusion 
Cytarabine, a polar nucleoside antileukemia drug with limited plasma stability and 
cell permeability, has been extensively evaluated by using prodrug and delivery 
systems. The prodrug attempts to improve delivery to target tissues, plasma stability, 
and therapeutic effect have been successful in generation of new drug conjugate 
molecules. Based on these concepts, a number of prodrugs and formulations were 
designed for cytarabine. Prodrug strategies included conjugation with fatty acids, amino 
acids, and substituted-phosphate derivatives of cytarabine. The activities of these 
conjugates were dependent on the rate of hydrolysis, cellular uptake, and resistance to 
cytidine deaminase. Among the prodrugs amino acid derivative ValCytarabine and fatty 
acid derivative CP-4055 (under Phase II trials) are being evaluated for the treatment of 
leukemia and solid tumors, respectively. Among lipophilic phosphodiester derivatives, 
cytarabine ocfosfate was approved for leukemia treatment. Furthermore, many delivery 
systems for improving cellular permeability, encapsulation, and the sustained release of 
cytarabine have been evaluated. Some include hydrogels, liposomes, niosomes, 
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nanoparticles, and polymers. The liposomal-cytarabine formulation (DepoCyt®) has 
been approved for the treatment of lymphomatous meningitis. Both prodrug and delivery 
systems have been effective in improving the biological profile of cytarabine. These 
approaches provide insights for designing prodrugs or delivery systems for other 
anticancer nucleoside drugs. Future investigations are required to generate additional 
prodrugs and delivery systems with optimal biological activity and delivery. Furthermore, 
a combination of using an optimal cytarabine prodrug with an appropriate delivery 
system or using cytarabine or cytarabine prodrugs in conjunction with different 
anticancer regimens and/or delivery systems may be needed to explore further 
applications of these strategies in anticancer research. 
 
5. Expert Opinion 
The concept of prodrug has been successfully used in improving the delivery, 
stability and pharmacological properties of drugs. The prodrug design is based on direct 
molecular changes on the drug to generate a dormant compound with appropriate 
physicochemical properties and desired biological activities. In case of nucleoside 
analogs, the prodrug designing concept is also used to bypass rate-limiting metabolic 
process by delivering nucleotides. It is not always easy to predict whether the dormant 
prodrug will be successful in generating desired properties. As shown with many 
designs for cytarabine prodrugs, modulating higher stability and better release in target 
tissues still remain a major challenge. Designing diverse number of prodrugs has 
allowed the discovery of compounds with optimal stability and release properties.  
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Nucleoside analogs have sugar and base moieties. The conjugation at 
appropriate positions is required for designing optimal prodrugs. Cytarabine has an 
arabinose sugar with three hydroxyl groups and a base with a free amino group. These 
functional groups generate high polarity and a limited cellular uptake. Furthermore, 
some of the functional groups, such as 4-amino and 5′-hydroxyl groups, are critical in 
stability and activation of the nucleoside, respectively. Cytarabine is inactivated by 
deamination of the base. Thus, some of the methods used for designing prodrugs of 
other anticancer or antiviral nucleosides may not be used here since additional care 
must be taken to prevent deamination. On the other hand, cytarabine is activated by 
conversion into nucleotides through phosphorylation at 5′ position. The designed 
prodrugs of cytarabine used the attachment of functional moieties at either the amino 
group of the base or 5′-hydroxy group arabinose sugar. The initial modifications used 
the fatty acids and different amino acids to improve the delivery and protection from 
deamination.  
The rationale behind 4-N modification with introducing the amide group and bulky 
fatty acids and amino acids was to block enzyme-mediated deamination into uridine. 
Although the stability of the compounds were enhanced by reducing deamination, 
modifications at N4 position led to reduction of activity of the compounds compared to 
the parent analog. A less unhydrolyzable amide and the presence of a bulky group 
(amino acids alone and/or with fatty acid) at position 4 made the parent drug less active 
possibly due to the presence of steric hindrance at the base during incorporation in 
nucleic acids. Thus, for improving the stability with N-4 substitution may not generate 
prodrugs with optimal biological properties. 
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Alternatively, introduction of functional moieties at 5′-OH involved with 
hydrolyzable ester groups gave products with improved pharmacological properties. 
The 5′-fatty acid derivative (ElacytTM) is under phase 3 clinical trials for anticancer 
studies (NCT01147939) by Clavis Pharma.  
Furthermore, prodrugs with a substituted phosphate group were expected to 
enhance biological activity by bypassing the first intracellular rate-limiting 
phosphorylation step. A simple lipophilic phosphate diester prodrug, cytarabine 
ocfosfate, was approved in 1992 for leukemia treatment. However, the 
phosphoramidate derivatives with stable P-N bond showed reduced antiproliferative 
activity in most of the cancer cells including leukemia and solid tumor lines. Thus, less 
stable phosphoester prodrugs are preferred to amidate counterparts for designing the 
next generation of lipophilic phosphate prodrugs of cytarabine. 
Less research has been carried out on conjugation of cytarabine with hydroxyl 
groups at 2′ and 3′ positions. It appears that substitution at 5′-position with fatty acids 
alone is beneficial in generating higher lipophilicity and cellular uptake, but may slow 
down the metabolic phosphorylation of cytarabine. Alternatively, it may be possible to 
design prodrugs with masked phosphate at 5′-position and lipophilic chains at 2′ or 3′ 
positions. It remains to be seen whether this strategy can combine the benefits of both 
approaches. 
Owing to limited cellular uptake of cytarabine, noncovalent methods using 
delivery systems or vehicles were expected to show great promise. These strategies will 
protect the chemical integrity of cytarabine and the compound is delivered in an intact 
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form. The encapsulation into protected sheaths like polymers, liposomes, hydrogels, 
and niosomes were expected to provide advantage of membrane transportation and 
continuous availability in the plasma over time. Among the evaluated delivery systems, 
the liposomal formulation was successful in enhancing the cytarabine half-life and 
treatment of lymphomatous meningitis. The hydrogels and niosomes were able to 
entrap polar cytarabine but the release from these systems remained slow due to strong 
interaction of drug with the sheath. The future studies need to focus on more 
optimization of delivery sheaths particularly hydrogel surfaces and nanoparticles to 
generate controlled or sustained release and appropriate balance of encapsulation and 
release properties.  
It remains to be determined whether an optimal cytarabine prodrug or those 
under evaluations (e.g., ElacytTM) can be combined with promising delivery systems 
such as liposomes. Furthermore, cytarabine is also used in combination with other 
anticancer drugs in treatment of patients. Further studies are required to determine 
whether combination of cytarabine prodrugs with other anticancer agents or using 
anticancer cocktails containing cytarabine prodrug or cytarabine with an appropriate 
delivery system can have any beneficial therapeutic effect in treatment of cancer 
patients. 
In summary, design of cytarabine prodrug derivatives and use of delivery 
systems have generated prodrugs or formulations that have optimal anticancer activity, 
stability, or delivery. The exploration of inactive prodrugs or not optimal delivery systems 
provided deep understanding of the underlying factors responsible for inactivity or 
incompatibility in formulation that led to the development of first generation of products 
33 
 
approved by FDA. Further improvement in design, modification in the drug molecule, or 
delivery sheath may lead to the second generation of compounds with broader 
applications. The same path may inspire the investigators to design more optimized 
anticancer nucleosides and other anticancer agents using the knowledge gained here. 
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